28-Mar-2024
TipRanks (Thu, 28-Mar 7:30 AM ET)
TipRanks (Tue, 26-Mar 10:55 AM ET)
PRNewswire (Tue, 26-Mar 7:18 AM ET)
Earnings week ahead: Walgreens Boots Alliance, Carnival, GameStop and more
Seeking Alpha News (Sun, 24-Mar 8:01 AM ET)
InvestorBrandMedia (Thu, 21-Mar 7:20 PM ET)
PRNewswire (Mon, 11-Mar 7:30 AM ET)
PRNewswire (Mon, 26-Feb 7:30 AM ET)
PRNewswire (Fri, 23-Feb 7:30 AM ET)
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of innovative-targeted therapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. Its most advanced products are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.
Actinium Pharmaceuticals (Delaware) trades on the AMEX stock market under the symbol ATNM.
As of March 28, 2024, ATNM stock price declined to $7.83 with 548,294 million shares trading.
ATNM has a beta of 0.70, meaning it tends to be less sensitive to market movements. ATNM has a correlation of 0.02 to the broad based SPY ETF.
ATNM has a market cap of $214.65 million. This is considered a Small Cap stock.
Last quarter Actinium Pharmaceuticals (Delaware) reported $0 in Revenue and -$.49 earnings per share. This fell short of revenue expectation by $-570,000 and exceeded earnings estimates by $.02.
In the last 3 years, ATNM stock traded as high as $15.12 and as low as $4.00.
The top ETF exchange traded funds that ATNM belongs to (by Net Assets): VTI, IWM, VXF, IWO, VTWO.
ATNM stock has underperformed the market in the last year with a return of -13.8%, while SPY returned +33.6%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in ATNM shares. However, ATNM has outperformed the market in the last 3 month and 2 week periods, returning +48.3% and +16.9%, while SPY returned +10.1% and +1.7%, respectively. This indicates ATNM has been having a stronger performance recently.
ATNM support price is $7.46 and resistance is $8.42 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ATNM stock will trade within this expected range on the day.